The abnormal HCG level detected during a doping control in 2022 shifted Torstein Træen’s career towards the medical side before launching it back onto the World Tour roads. This case, which has become a reference in the field to illustrate the cooperation between anti-doping agencies and early medical diagnosis, deserves a technical reading that mainstream narratives often overlook.
Detection by anti-doping and diagnosis of testicular cancer
The discovery of Træen’s cancer did not result from a routine medical examination or a clinical symptom. It was an abnormal HCG level detected during a doping control that raised the alarm. Human chorionic gonadotropin, a classic tumor marker for testicular germ cell tumors, is on the list of monitored substances because it stimulates testosterone production.
In the usual protocol, an atypical result for HCG leads to a disciplinary procedure. Here, medical guidance prevailed. The Norwegian rider was redirected to a diagnostic pathway that confirmed testicular cancer, which was subsequently operated on.
This case illustrates a rare scenario where the anti-doping system saves a life rather than sanctioning an athlete. Authorities have since cited it as a positive example of the dual function of the biological passport: to protect sporting integrity and, at times, to detect a serious pathology. To delve deeper into Torstein Traeen’s journey against cancer, the medical and sporting timeline has been documented in detail.
Progression in stages: from the 2024 Tour de Suisse to the yellow jersey in 2026
We too often see in media coverage a shortcut of “cancer then yellow jersey” that masks the reality of a structured return over several seasons. Træen did not emerge from nowhere at the 2026 Tour de France. His rise in power follows a perfectly identifiable step-by-step construction logic.
2023 Season: comeback and early signals
As early as 2023, Træen reappears in the top 10 in mountain races. His eighth place at the Critérium du Dauphiné indicates a return of his abilities at altitude, even if the level is not yet that of a grand tour leader.
2024 Season: first major victory
The confirmation comes with his victory at the 2024 Tour de Suisse. This result repositions him among the best climbers in the peloton and validates his ability to sustain effort in a week-long stage race.
2025 Season: successful test over three weeks
The 2025 Vuelta serves as the real crash test. Træen wears the red leader’s jersey for four stages and finishes ninth in the general classification. Holding a three-week grand tour at this level after cancer surgery two and a half years earlier is proof that the physiological foundation has been rebuilt.
2026 Tour de France: the yellow jersey
Taking the yellow jersey at the 2026 Tour de France thus fits into a logical sequence. The progression is not a miracle but the result of methodical reconstruction work over four seasons.
- 2022: diagnosis and surgery for testicular cancer
- 2023: competitive return, top 10 at the Critérium du Dauphiné
- 2024: victory at the Tour de Suisse, first major success post-cancer
- 2025: red jersey at the Vuelta for four stages, ninth overall
- 2026: yellow jersey at the Tour de France
Climber profile and positioning against Pogačar
Træen has a pure climber profile, with a power-to-weight ratio that places him among the best in high mountains. His lead over Tadej Pogačar during the phase when he wore the yellow jersey reached nearly eight minutes, a considerable gap that can partly be explained by the race strategy of the Bahrain Victorious team and the tactical positioning of the favorites at the start of the Tour.
Reducing this lead to a mere escape effect would be an analytical error. Træen demonstrated at the 2025 Vuelta that he could keep pace with the leaders over three weeks. The question is no longer whether he can compete in the mountains, but whether he has the team and roster depth necessary to withstand the offensive from UAE or Visma throughout the Tour.
His case raises a tactical question that we encounter increasingly in modern cycling: can a rider with a still modest record turn an opportunity yellow jersey into sustainable leadership in the race? The answer depends less on his watts than on his team’s ability to control the race in flat and time trial stages.
Medical and sporting impact: what the Træen case changes
Træen’s return to the highest level after testicular cancer is not unprecedented in sports, but it renews the subject at a time when post-treatment follow-up protocols are more rigorous. Several elements distinguish his case.
- Detection by the anti-doping system (and not by a personal medical examination) opens a debate on the public health role of the biological passport
- The time between surgery and return to the forefront (less than two years for a top 10 in World Tour) is remarkably short
- The continuous progression over four seasons rules out the hypothesis of an isolated peak and suggests a complete physiological recovery
For teams and their medical staff, the Træen case demonstrates that an early diagnosis of germ cell tumor, surgically treated without heavy chemotherapy, does not prevent a return to elite performance. The determining factor remains the speed of diagnosis, here enabled by a doping control that, for once, fulfilled an unexpected function.
The trajectory of Torstein Træen is not a fairy tale in cycling. It is a clinical and sporting case whose technical reading, season by season, shows that a sustainable return to the highest level after cancer is still possible when the diagnosis is early and the reconstruction methodical.